No Data
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
Yiqing Chen and Yifei Jiang have been appointed as independent non-executive directors of Baixin Security-B (02185).
Pakson International Company Limited (02185) announced that Mr. Chan Shang Wei and Mr. Zheng Rongyao have resigned from their positions as...
Baixinan-B proposes to appoint Chen Yiqing as an independent non-executive director
Baixinan-B (02185) issued an announcement. The board of directors has been informed by Chen Shangwei and Zheng Rongyao that they will resign as independent non-executive directors to spend more time on their other work. Their resignations will take effect after the AGM. Until then, Chen Shangwei and Zheng Rongyao will continue to perform their duties as independent non-executive directors. Following the resignation of Chan Sheung-wai and Cheng Wing-yiu, Chan Sheung-wai will no longer serve as Chairman of the Audit Committee and a member of the Remuneration Committee and Nomination Committee, and Cheng Wing-yiu will no longer serve as a member of the Audit Committee and Remuneration Committee. After considering the recommendation of the Nomination Committee, the Director
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
BIOHEART-B: 2023 ANNUAL REPORT
No Data
